Your browser doesn't support javascript.
loading
A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.
Kamegai, Kohei; Iwamoto, Noriko; Togano, Tomiteru; Maeda, Kenji; Takamatsu, Yuki; Miyazato, Yusuke; Ishikane, Masahiro; Mizokami, Masashi; Sugiyama, Masaya; Iida, Shun; Miyamoto, Sho; Suzuki, Tadaki; Ohmagari, Norio.
Afiliación
  • Kamegai K; National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwamoto N; National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: nkinoshita@hosp.ncgm.go.jp.
  • Togano T; National Center for Global Health and Medicine, Tokyo, Japan.
  • Maeda K; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute.
  • Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute.
  • Miyazato Y; National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishikane M; National Center for Global Health and Medicine, Tokyo, Japan.
  • Mizokami M; National Center for Global Health and Medicine, Tokyo, Japan.
  • Sugiyama M; National Center for Global Health and Medicine, Tokyo, Japan.
  • Iida S; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ohmagari N; National Center for Global Health and Medicine, Tokyo, Japan.
Int J Infect Dis ; 121: 85-88, 2022 Aug.
Article en En | MEDLINE | ID: mdl-35500795

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Canadá